Key result
Cancer is associated with an estimated 5-fold increased risk of venous thromboembolism compared with the general population, with risk varying significantly by cancer type and stage.
Effect estimate: 5-fold increase
Cancer-associated thrombosis risk varies significantly by cancer type, with hematological, lung, pancreas, stomach, bowel, and brain cancers carrying higher risk.
Cancer‐associated thrombosis (CAT), in the form of venous thromboembolism (VTE) or arterial events, is the most common morbidity in cancer patients and is associated with higher mortality rates.1 It is estimated that VTE occurrence is increased 5‐fold in cancer patients compared with the general population.2 Not all cancers are created equal in terms of VTE risk. Hematological malignancies, lung, pancreas, stomach, bowel, and brain cancers are associated with higher risk. In contrast, breast and prostate cancers are considered low risk for VTE, but progression of the disease to metastatic malignancies is known to increase significantly the thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Denis et al. (2022) conducted an editorial in Cancer-associated thrombosis. Cancer vs. General population was evaluated on Venous thromboembolism (VTE) (5-fold increase). Cancer is associated with an estimated 5-fold increased risk of venous thromboembolism compared with the general population, with risk varying significantly by cancer type and stage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: